An observational study in Atrial Fibrillation (AF), sponsored by Esbjerg Hospital - University Hospital of Southern Denmark. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Esbjerg Hospital - University Hospital of Southern Denmark · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Atrial Fibrillation with a site in Denmark — 31 open to participants now, 48 under way, 3 of them phase 3. Atrial Fibrillation · Denmark.
Among the 176 studies in Atrial Fibrillation with a site in Denmark, this one is the 3rd largest by enrollment of the 36 observational ones that give a count, is one of 7 that started in 2025, is one of 36 observational ones, and was the 158th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →31 of the 176 studies in Atrial Fibrillation with a site in Denmark are open now. Recruiting first, the newest first:
University College Copenhagen · Sites in Denmark
Ages 18+
Abbott Medical Devices · Sites in Denmark, Belgium, Czechia and 7 more countries
Ages 18+
Acesion Pharma · Sites in Denmark, Bulgaria, Germany and 5 more countries
Ages 18+
Herlev and Gentofte Hospital · Sites in Denmark
University of L'Aquila · Sites in Denmark, Croatia, Egypt and 12 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 17 · Phase 3 32 · Phase 4 19
First in 1999; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30,882 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 273 across the 140 interventional studies, 391 across the 36 observational. Of the 118 that completed or were terminated, 40 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 176 have an industry lead sponsor. The 10 most frequent:
Esbjerg Hospital - University Hospital of Southern Denmark is the lead sponsor of 51 studies on the registry; 16 are open to participants now.
Esbjerg Hospital - University Hospital of Southern Denmark has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
15 of the studies in Atrial Fibrillation with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
| NCT07428564Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE PRO Software in Participants With PsAF | 2026-12-30 |
| NCT05104658Center for Clinical Research and PreventionHeart Rehabilitation for All | 2026-12-31 |
| NCT03862859Nicholas CarlsonThe Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis | 2027-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 176 studies in Atrial Fibrillation with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this survey- and registry-based study is to learn about the cardiac rehabilitation needs of individuals with atrial fibrillation (AF). The main objectives of the study is to:
Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults globally. It poses significant public health challenges and is associated with substantial morbidity and mortality. AF affects quality of life with an enlarged symptom burden. To improve life expectancy and quality of life, medical treatment along with risk factor management and cardiac rehabilitation is needed. In many countries, referral to cardiac rehabilitation remains low. Furthermore, no guidelines or evidence provides details on whom should be referred. Thus, we do not know how many individuals with AF presents with cardiac rehabilitation needs.
This study is a survey and registry-based study. Danish health registries are used to draw a population of individuals with incident AF in 2023-2024. Following the exclusion criteria, these will receive a survey covering the described outcomes which are used to investigate needs of rehabilitation. A statistical descriptive analysis will be performed to describe needs and patient-preferences for CR components.
Registry-based. The study population is drawn from Danish Health Registries and receive an online questionnaire.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Population with incident AF in Denmark in 2023-2024
Atrial fibrillation related quality of life
Atrial fibrillation related quality of life by ASTA HRQoL scale (The Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia). The ASTA HRQoL scale has 13 items and describes the arrhythmia's influence on daily life situation with a seven items physical subscale (items 1-5, 10 and 12) and a six items mental subscale (items 6-9, 11 and 13). We will be using both the total and subscale scores as recommended. The response alternatives from 0 to 3: "No (0), Yes, to a certain extent (1), Yes, quite a lot (2), Yes, a lot (3)". Scoring for the ASTA HRQoL total scale ranges from 0 (best possible HRQoL) to highest 39 (worst possible HRQoL). Higher scores reflect a worse effect on HRQoL due to the heart rhythm disturbance. ASTA's physical subscale ranges from 0 to 21 and the mental subscale ranges from 0 to18.
Time frame: At enrollment
Atrial fibrillation related symptom burden
AF6 questionnaire. Patients chose a number on a Likert scale from 0 to 10, where 0 means no and 10 severe symptoms or difficulties. The scores of the six questions are added into a single global score. The recall period for the instrument is the most recent 7 days.
Time frame: At enrollment
General well-being
WHO5. The WHO-5 is a five-item scale measuring well-being and life satisfaction within the past 2 weeks and the scale is operationalized using a 0-100 score, with higher values indicating a higher level of well-being and life satisfaction. Scores below 50 indicate poor well-being.
Time frame: At enrollment
Anxiety
ASS-2 has the purpose of screening for anxiety within the past 2 weeks. Higher score of ASS-2 indicates a higher symptom level of anxiety.
Time frame: At enrollment
Depression
MDI-2 has the purpose of screening for depression within the past 2 weeks. Higher score indicates a higher symptom level of depression.
Time frame: At enrollment
Medicine adherence
MARS-5 (Medication Adherence Report Scale). Items scored as 5 = never to 1 = always, i.e. high scores = high adherence. Scores are added together to form a scale score (range = 5 to 25). An adjusted mean score is calculated by dividing the scale mean by the number of items in the scale (range 1-5).
Time frame: At enrollment
Risk factor status
Obesity, physical inactivity, smoking and alcohol habits
Time frame: At enrollment
Comorbidity
Hypertension, diabetes, sleep apnoea, other cardiac diseases
Time frame: At enrollment
General health status
EQ-5D-5L. Responses are coded as single-digit numbers expressing the severity level selected in each dimension. For instance, 'slight problems' (e.g. 'I have slight problems in walking about') is always coded as '2'. The digits for the five dimensions can be combined in a 5-digit code that describes the respondent's health state; for instance, 21111 means slight problems in the mobility dimension and no problems in any of the other dimensions. The EQ VAS records the respondent's overall current health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' (100) and 'The worst health you can imagine' (0). The EQ VAS provides a quantitative measure of the patient's perception of their overall health.
Time frame: At enrollment
Demographic data
Age, gender, civil status, living situation, region of Denmark, educational level, occupational status, ethnicity, socio-economic classification and family disposable income.
Time frame: At enrollment
Outcomes important for the overall assessment of cardiac rehabilitation needs
Questions regarding family relations, health literacy (HLS-EU-Q12), management of heart disease, previous provided information of cardiac rehabilitation and motivation for these interventions forwardly.
Time frame: At enrollment
Plan to share: No — Unless follow-up studies using the same study population is planned later on, data (IPD) will not be shared.
Ran from Jun 2025 to primary completion in Dec 2025, 6 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Jul 2025 → Dec 2025 and completion Jul 2025 → Dec 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Esbjerg Hospital - University Hospital of Southern Denmark